This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gustafsson, I.
Right arrow Articles by Cars, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gustafsson, I.
Right arrow Articles by Cars, O.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 353-355, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.353-355.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Pharmacodynamic Studies of Activities of Ketolides HMR 3647 (Telithromycin) and HMR 3004 against Extracellular or Intracellular Helicobacter pylori

I. Gustafsson,1 L. Engstrand,1 and O. Cars2,*

Department of Clinical Bacteriology,1 and Antibiotic Research Unit, Department of Infectious Diseases,2 Uppsala University, Uppsala, Sweden

Received 24 April 2000/Returned for modification 21 August 2000/Accepted 25 October 2000

The pharmacodynamic properties of the ketolides HMR 3647 (telithromycin) and HMR 3004 were studied against Helicobacter pylori. Both ketolides showed a pronounced concentration-dependent killing, a significant postantibiotic effect, a long postantibiotic sub-MIC effect, and a reduction of intracellular H. pylori.

* Corresponding author. Mailing address: Department of Infectious Diseases, University Hospital, SE-751 85 Uppsala, Sweden. Phone: 46 (18) 611 56 72. Fax: 46 (18) 611 56 50. E-mail: otto.cars{at}smi.ki.se.

Antimicrobial Agents and Chemotherapy, January 2001, p. 353-355, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.353-355.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Jodlowski, T. Z, Lam, S., Ashby, C. R Jr (2008). Emerging Therapies for the Treatment of Helicobacter pylori Infections. The Annals of Pharmacotherapy 42: 1621-1639 [Abstract] [Full Text]  
  • Yanagihara, K., Morinaga, Y., Nakamura, S., Seki, M., Izumikawa, K., Kakeya, H., Yamamoto, Y., Yamada, Y., Kamihira, S., Kohno, S. (2008). Subinhibitory concentrations of telithromycin, clarithromycin and azithromycin reduce methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo. J Antimicrob Chemother 61: 647-650 [Abstract] [Full Text]  
  • Ackermann, G., Rodloff, A. C. (2003). Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide. J Antimicrob Chemother 51: 497-511 [Abstract] [Full Text]  
  • Fahey, J. W., Haristoy, X., Dolan, P. M., Kensler, T. W., Scholtus, I., Stephenson, K. K., Talalay, P., Lozniewski, A. (2002). Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl. Acad. Sci. USA 99: 7610-7615 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»